hotspot -WSS

hotspot

author：knowledge 2025-09-27 17:02:04 - browse：15

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： CDC concerned about possible undetected monkeypox spread in U.K.

explore

WSS

Kansas bar where gunfire wounded 9 last month closes permanently

The strategy behind pharma's lawsuits over drug pricing reform

Why drug prescriptions should include diagnoses

Sweden knocks USA out of World Cup in penalty kicks

Disclosing genetic information: not as worrisome as once feared

Weight bias in eating disorder treatment complicated by new weight loss drugs

hotspot

hotspot

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

#NeedHerScience: shining a light on gender disparities in medicine

Duchenne breakthrough therapy leaves behind pioneering families

'Brian's Song' at 50 still offers lessons about cancer for today

Medical leaders decry Supreme Court decision on affirmative action

Judge in Trump's classified documents case questions use of out

Walensky prepares to leave CDC — and Congress — behind

Feed a cold, starve a fever? Here’s what science says

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In areas with more Black doctors, Black people live longer

focus

With FDA staff opposed to Sarepta therapy, top official intervened

Do masks work? RCTs can't tell us

Why are elite athletes different? Take a look at their microbes

Donald Trump's relentless attacks on special counsel Jack Smith

With FDA staff opposed to Sarepta therapy, top official intervened

Sweden knocks USA out of World Cup in penalty kicks

focus

hotspot

explore

explore